Logo

Celltrion's Bevacizumab Biosimilar (CT-P16) Enters into Global Phase III Clinical trial for Treating Colorectal Cancer

Share this

Celltrion's Bevacizumab Biosimilar (CT-P16) Enters into Global Phase III Clinical trial for Treating Colorectal Cancer

 

Shots: 

   • Celltrion has completed Phase I on safety and efficacy of CT-P16 in June 18 

   • CT-P16 extended to Phase III as planned by submission of application to National Authority of Medicines and Health Products- I.P. (Infarmed) of Portugal 

 • Celltrion has plan to conduct Phase III clinical trial for CT-P16 in about 150 sites with 20 countries starting with Portugal- Europe- Asia and South America

 

Ref: Celltrion  | Image: Forbes

 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions